Immuron Limited (IMRN)
Makes antibody-based medicines to treat digestive infections and traveler's diarrhea.
$1.11-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.7%
The outlook
IMRN is trading well below its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits significantly above the current price. The stock remains thinly traded relative to its recent volatility.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range25% of the way from its 52-week low to high
Price targetAvg target +251% vs current price
Market cap
$9.0M
52-wk high
$2.39
52-wk low
$0.68
50-day avg
$1.16
200-day avg
$1.14
Trailing P/E
—